For Q1 FY2026 (ended March 31, 2026), Edwards Lifesciences reported revenue of $1,648.6 million, up 16.7% year-over-year. Net income was $380.7 million, up 6.3%, and diluted EPS was $0.66, up 8.2%. Operating income rose 21.0% to $477.6 million. The company had $2,445.5 million in cash, $10,327.5 million in equity, and $598.5 million in long-term debt.
•Revenue increased 16.7% YoY to $1,648.6 million.
•Net income grew 6.3% YoY to $380.7 million.
•Diluted EPS rose 8.2% to $0.66.
•Operating income improved 21.0% to $477.6 million.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Edwards Lifesciences provides products and technologies to treat advanced cardiovascular diseases globally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system Transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands
Surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name. Its portfolio also includes INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology, KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures, and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Founded in 1958, Edwards Lifesciences is headquartered in Irvine, California.
Edwards Lifesciences Corporation is a global leader in medical devices for treating advanced cardiovascular diseases. The company specializes in transcatheter heart valve replacement products, including the Edwards SAPIEN family of valves for minimally invasive aortic valve replacement. It also offers repair and replacement solutions for mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. Additionally, Edwards provides surgical structural heart solutions such as the INSPIRIS RESILIA aortic valve, which features RESILIA tissue and VFit technology, and the KONECT RESILIA tissue valve conduit for complex procedures. The company distributes its products through a direct sales force and independent distributors worldwide.
Where is Edwards Lifesciences (EW) listed and what currency does it trade in?
Edwards Lifesciences is listed on the New York Stock Exchange (NYSE) under the ticker symbol EW. Its shares are traded in US Dollars (USD), reflecting its primary listing in the United States. As a US-based company, its financial reporting and stock trading are conducted in USD, making it accessible to investors on major US exchanges.
What sector and industry does Edwards Lifesciences (EW) belong to?
Edwards Lifesciences operates in the Healthcare sector, specifically within the Medical Devices industry. This classification reflects its focus on developing and manufacturing innovative medical technologies, particularly for cardiovascular diseases. The company's products are used in hospitals and clinics for minimally invasive and surgical heart valve procedures, positioning it as a key player in the medical device market.
Where is Edwards Lifesciences (EW) headquartered and what markets does it serve?
Edwards Lifesciences is headquartered in Irvine, California, United States. Founded in 1958, the company serves global markets, providing products and technologies to treat advanced cardiovascular diseases worldwide. Its distribution network includes a direct sales force and independent distributors, enabling it to reach healthcare providers across different regions. The company's focus on transcatheter and surgical heart valve solutions addresses needs in both developed and emerging markets.
What are the main products and technologies offered by Edwards Lifesciences (EW)?
Edwards Lifesciences offers a comprehensive portfolio of products for cardiovascular disease treatment. Its transcatheter heart valve replacement products include the Edwards SAPIEN family for minimally invasive aortic valve replacement. For mitral and tricuspid valve diseases, it provides the PASCAL and EVOQUE brands. Surgical structural heart solutions include the INSPIRIS RESILIA aortic valve with RESILIA tissue and VFit technology, the KONECT RESILIA pre-assembled tissue valve conduit, and the MITRIS RESILIA valve. These products are designed to improve patient outcomes through advanced tissue processing and minimally invasive delivery.